Comments on article by Albers et al: "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy".
Chiu
Chih-Chiang
CC
Lu
Mong-Liang
ML
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001569:Benzodiazepines / Q000008:administration & dosage / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016666:Fluvoxamine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine; D016666:Fluvoxamine